COVID-19 vaccine sales for 2022 approximately $18.4 billion (unaudited)
Reiterating 2023 expected minimum COVID-19 vaccine sales of approximately $5.0 billion; continue to expect additional contracts for 2023
Company continues to scale with 48 programs in development, including 36 in ongoing clinical studies, and is increasing R&D investment to an expected $4.5 billion for 2023
Pivotal Phase 3 RSV study of mRNA-1345 in older adults (≥ 60 yrs.) has now accrued the cases required to complete our first interim efficacy analysis
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients. Phase 3 study in melanoma patients to start in 2023, with rapid expansion to additional tumor types
Phase 1/2, multiple ascending dose Paramount study of propionic acidemia (PA) candidate (mRNA-3927) is ongoing
https://finance.yahoo.com/news/moderna-announces-advances-across-mrna-120000769.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.